Gene · 325
Papers4,193
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,021 to 1,040 of 4,193
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach. | Int J Mol Sci | 2020 | 32375302 | PubTator, text mining | PubMed |
| Oxidative Stress and Inflammatory Markers PTX3, CypA, and HB-EGF: How Are They Linked in Patients With STEMI? | Angiology | 2020 | 32372694 | PubTator, text mining | PubMed |
| Plasma pentraxin 3 is higher in early ovarian hyperstimulation syndrome than in uncomplicated in vitro fertilization cycle of high-risk women. | Arch Gynecol Obstet | 2020 | 32372340 | PubTator, text mining | PubMed |
| Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods. | Adv Drug Deliv Rev | 2020 | 32360155 | PubTator, text mining | PubMed |
| Serum pentraxin 3 as a clinical biomarker of branch atheromatous disease: a marker of brain ischaemia or an atherotrombosis marker? | Eur J Neurol | 2020 | 32359025 | PubTator, text mining | PubMed |
| Mitochondrial oxidative phosphorylation in peripheral blood mononuclear cells is decreased in chronic HIV and correlates with immune dysregulation. | PLoS One | 2020 | 32353005 | PubTator, text mining | PubMed |
| PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. | Aging (Albany NY) | 2020 | 32345771 | PubTator, text mining | PubMed |
| Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to. | Ann Hematol | 2020 | 32333155 | PubTator, text mining | PubMed |
| FOXL2 directs DNA double-strand break repair pathways by differentially interacting with Ku. | Nat Commun | 2020 | 32332759 | PubTator, text mining | PubMed |
| Advances in the Treatment of Cardiac Amyloidosis. | Curr Treat Options Oncol | 2020 | 32328845 | PubTator, text mining | PubMed |
| Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability. | J Comp Neurol | 2020 | 32323319 | PubTator, text mining | PubMed |
| Effect of self-assembling peptide P11-4 on orthodontic treatment-induced carious lesions. | Sci Rep | 2020 | 32321955 | PubTator, text mining | PubMed |
| Editorial: Innate Immunity in the Context of Osteoimmunology. | Front Immunol | 2020 | 32318075 | PubTator, text mining | PubMed |
| Identification of HO-1 as a novel biomarker for graft acute cellular rejection and prognosis prediction after liver transplantation. | Ann Transl Med | 2020 | 32309368 | PubTator, text mining | PubMed |
| Non-Coding RNAs in CD4+ T Cells: New Insights Into the Pathogenesis of Systemic Lupus Erythematosus. | Front Immunol | 2020 | 32308657 | PubTator, text mining | PubMed |
| Expression and Purification of Full-Length and Domain-Fragment Recombinant Pentraxin 3 (PTX3) Proteins from Mammalian and Bacterial Cells. | Methods Mol Biol | 2020 | 32306315 | PubTator, text mining | PubMed |
| Estradiol Valerate in COC Has More Favorable Inflammatory Profile Than Synthetic Ethinyl Estradiol: A Randomized Trial. | J Clin Endocrinol Metab | 2020 | 32303765 | PubTator, text mining | PubMed |
| Transforming growth factor-β1 suppress pentraxin-3 in human orbital fibroblasts. | Endocrine | 2020 | 32300954 | PubTator, text mining | PubMed |
| Management of myelofibrosis after ruxolitinib failure. | Leuk Lymphoma | 2020 | 32297800 | PubTator, text mining | PubMed |
| Celluar Folding Determinants and Conformational Plasticity of Native C-Reactive Protein. | Front Immunol | 2020 | 32296446 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/325/papers?page=52